CARDIOVASCULAR EVENTS IN POLYCYSTIC OVARY SYNDROME

Similar documents
Rotterdam Criteria 9/30/2017. A Changing Paradigm in PCOS. Polycystic Ovary Syndrome - Is the Cardiometabolic Risk Increased After Menopause?

Hyperandrogenism, PCOS and obesity after menopause : Meet the experts. Polycystic ovaries beyond menopause

Diabetes and Cardiovascular Risks in the Polycystic Ovary Syndrome

Attendee become familiar with the evidence for the major risk factors for CVD Attendee will become familiar with the

Thoughts on PCOS Female Androgenization Syndrome FAS

The Impact of Insulin Resistance on Long-Term Health in PCOS

Diabetes Mellitus: A Cardiovascular Disease

CARDIOVASCULAR RISK FACTORS. Harpal S Randeva. Warwick Medical School University of Warwick, UK

CREATING A PCOS TREATMENT PLAN. Ricardo Azziz, M.D., M.P.H., M.B.A. Georgia Regents University

ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)

12/13/2017. Important references for PCOS. Polycystic Ovarian Syndrome (PCOS) for the Family Physician. 35 year old obese woman

Addressing Practice Gaps in PCOS

Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018

Update on PCOS Research. Richard S. Legro, M.D., Penn State College of Medicine, Dept of Ob/Gyn, Hershey, PA, USA

Clinical Manifestations of the Polycystic Ovary Syndrome at Menopausal Age

Dr Stella Milsom. Endocrinologist Fertility Associates Auckland. 12:30-12:40 When Puberty is PCO

UPDATE: Women s Health Issues

Amenorrhoea: polycystic ovary syndrome

On Diseases Of Menstruation And Ovarian READ ONLINE

CLINICAL OUTCOME Vs SURROGATE MARKER

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups

Reproductive Health in Non Alcoolic Fatty Liver Disease (NAFLD)

Overview of Reproductive Endocrinology

Risk of cardiovascular events in patients with polycystic ovary syndrome

Polycystic Ovary Syndrome

Polycystic Ovary Syndrome

WHY NEW DIAGNOSTIC CRITERIA FOR DIFFERENT PCOS PHENOTYPES ARE URGENTLY NEEDED

What every dermatologist should know about Polycystic Ovary Syndrome (PCOS)

BACKGROUNDER. Pregnitude A Fertility Dietary Supplement for Reproductive Support Offers an Additional Option for Women Who Are Trying to Conceive

Polycystic Ovarian Syndrome. Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology

X/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Copyright 2006 by The Endocrine Society doi: /jc.

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital

Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance related polycystic ovary syndrome

Metabolic changes in menopausal transition

Prevalence of Polycystic Ovarian Syndrome among urban adolescent girls and young women in Mumbai

JAMA. 2011;305(24): Nora A. Kalagi, MSc

Polycystic Ovary Disease: A Common Endocrine Disorder in Women

Polycystic Ovary Syndrome

Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?

Polycystic Ovary Syndrome

Coronary Heart Disease in Women Go Red for Women

clinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome

PCOS and Obesity DUB is better treated by OCPs

Estrogens vs Testosterone for cardiovascular health and longevity

Metformin and Pioglitazone in Polycystic Ovarian Syndrome: A Comparative Study

Elevated Risk of Cardiovascular Disease Prior to Clinical Diagnosis of Type 2 Diabetes

Case Questions. Polycystic Ovarian Syndrome: Treatment Goals and Options. Differential Diagnosis of Hyperandrogenic Anovulation

European Journal of Endocrinology (2006) ISSN

Abnormal Uterine Bleeding Case Studies

PCOS. pregnancy complications. Prof. Bart CJM Fauser. Dept. Reproductive Medicine and Gynecology. University Medical Center, Utrecht, The Netherlands

Outline. Diagnos(c Criteria and PCOS features Diagnos(c Criteria by age Reproduc(ve Care for the woman with PCOS, a focus on fer(lity and pregnancy.

Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes

Diabetes and the Heart

INSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME An Overview

Finally AEPCOS is seeking a new Editor of AEPCOS Newsletter. V o l u m e 4, I s s u e 1 M A R C H 3 1,

AEPCOS NewSLET TER A N D R O G E N E X C E S S & P C O S S O C I E T Y. V o l u m e 2, I s s u e 12 D E C E M B E R 3 1,

PCOS Awareness Symposium Atlanta September 24 th, Preventing Diabetes & Cardiovascular Disease in PCOS

Does Ovarian Cysts affect your Fertility?

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?

Polycystic ovarian syndrome Can lifestyle modifications help?? Dr Saloni Assistant Professor, Deptt of OBG BPSGMC for Women, Khanpur Kalan

The TNT Trial Is It Time to Shift Our Goals in Clinical

Polycystic Ovary Syndrome (PCOS):

Reproductive outcome in women with body weight disturbances

Diabetes: Across the Lifespan Friday, October 17, Obesity, Insulin Resistance and Type 2 Diabetes Cardiovascular Risks in Children.

Original Article Pregnancy Complications - Consequence of Polycystic Ovary Syndrome or Body Mass Index?

Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,

Lipid Management 2013 Statin Benefit Groups

2017 Hot topics in cardiometabolism: an interactive update

Diabetes Day for Primary Care Clinicians Advances in Diabetes Care

Metfornim and Pioglitazone in polycystic ovarian syndrome: A comparative study

13 th Annual Women s Health Day PCOS. Saturday 02/09/2017 Dr Mathias Epee-Bekima O&G Consultant KEMH

SCIENTIFIC STUDY REPORT

The Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk

A nationwide population-based study. Pai-Feng Hsu M.D. Shao-Yuan Chuang PhD

New PCOS guidelines: What s relevant to general practice

Study No.: Title: Rationale: Phase Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Metabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology

The ACCELERATE Trial

Metformin in early pregnancy and abortions. Laure Morin-Papunen, MD, PhD Dept. of Obstetrics and Gynecology University Hospital of Oulu, Finland

METABOLIC SYNDROME IN REPRODUCTIVE FEMALES

Prevalence of polycystic ovarian syndrome in the Buraimi region of Oman

ORIGINAL ARTICLE. COMPARISON OF METFORMIN AND PIOGLITAZONE IN PCOS Archana V. Rokade, Javdekar D. P, Patange R. P.

About PCOS. About PCOS

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

The prevalence of diabetes mellitus (DM) is increasing at

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

PCOS IN ADOLESCENTS: EARLY DETECTION AND INTERVENTION

Clinical Study Hyperandrogenism Does Not Influence Metabolic Parameters in Adolescent Girls with PCOS

Welcome and Introduction

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Richard S. Legro, M.D., Penn State College of Medicine, Dept of Ob/Gyn, Hershey, PA, USA

PCOS guidelines: What s relevant to general practice

HDL-C. J Jpn Coll Angiol, 2008, 48: NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart

Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.

AEPCOS NewSLET TER A N D R O G E N E X C E S S & P C O S S O C I E T Y. V o l u m e 3, I s s u e 6 J U L Y 3 1,

Can Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome?

Fasting or non fasting?

Achieving Pregnancy: Obesity and Infertility. Jordan Vaughan, MSN, APN, WHNP-BC Women s Health Nurse Practitioner Nashville Fertility Center

Does PCOS Compromise the oocyte and embryo quality or the endometrium?

Transcription:

CARDIOVASCULAR EVENTS IN POLYCYSTIC OVARY SYNDROME Enrico Carmina Executive Director & CEO of Androgen Excess & PCOS Society Professor of Endocrinology Department of Health Sciences and Mother and Child Care, University of Palermo, Palermo, Italy

LONG TERM RISKS IN PCOS Young PCOS women present an increased risk of type II diabetes cardiovascular diseases chronic liver disease endometrial cancer

INCREASED CV RISK IN YOUNG PCOS WOMEN A large number of studies has shown increased CV risk in young PCOS women Almost all CV risk factors including metabolic syndrome, atherogenic dyslipidemia, LDL levels, hypertension and C-reactive protein have been found elevated in young women with PCOS

CV EVENTS IN PCOS It is still unclear whether CV events are increased in women with PCOS Contrasting data have been published and the quality of many studies is relatively low

CV EVENTS IN PCOS WOMEN DURING REPRODUCTIVE AGE In a large Australian study (Hart et al JCEM 2015) hospitalization for cardiovascular diseases was increased in young PCOS women (mean age 35 years) Ischemic heart disease 0.8% vs 0.2% in general population Cerebrovascular ischemic disease 0.6% vs 0.2 in general population Although this approach has many biases, it suggests a larger number of cardiovascular events in young population with PCOS

CV EVENTS IN PCOS WOMEN DURING REPRODUCTIVE AGE An inherent difficulty is linked to the low number of CV events in young population In general population the prevalence of myocardial infarction at the age of 35 years is only 1.22 x 10,000 individuals A hospitalization based study may over-estimate the phenomenon Anyway, a 4 times increase may mean 5 cases of ischemic heart disease x 10,000 individuals

RELATIVE RISK FOR CARDIOVASCULAR EVENTS IN NORMAL WOMEN DURING REPRODUCTIVE AGE Number of events for 10,000 person-year Myocardial infarction Stroke 15-19 years 0.04 0.34 20-24 years 0.07 0.56 25-29 years 0.20 1.05 30-34 years 0.50 1.54 35-39 years 1.22 2.33 40-44 years 2.54 3.92 45-49 years 3.82 6.44 Modified from Lidegaard et al. NEJM 2012:366:2257-66

NO INCREASED CV EVENTS IN FOLLOW-UP OF PCOS PATIENTS In our follow-up study, no main CV events were observed in PCOS women when they moved from their 20s to early 40s In several patients atherosclerotic plaques were present in their young age but resolved before the patients reached the menopausal age It suggests that the flexibility of CV system during young age may reduce the number of expected events

AGING AND CV DISEASES In the normal population, occurrence of cardiovascular diseases is strictly related to age The number of main cardiovascular events is very low during young fertile age and starts increasing during late reproductive age The number of cardiovascular events strongly increases during 50s

CARDIOVASCULAR EVENTS IN AGED PCOS One study that reviewed death certificates of 786 women in the United Kingdom who were diagnosed with PCOS at an average age of 26.4 years and followed for an average duration of 30 years failed to show a statistically significant increase in cardiovascular mortality (Pierpoint et al. J Clin Epidemiol 1998;51:581-6) However, this study has been criticized because the diagnosis of PCOS was based on historical data during a very large period (hospital records between 1930 and 1979) and was not supported by hormonal studies

CARDIOVASCULAR EVENTS IN AGED PCOS In a successive report, the same authors (Wild et al Clin Endocrinol 2000;52:595-600) have studied a more restricted but more carefully selected cohort of patients (309 postmenopausal women who were diagnosed as affected by PCOS, before 1979, in United Kingdom). The authors did not observe any increase in coronary heart disease (odd ratio 1.5) but noted a higher prevalence of cerebrovascular accidents (odd ratio 2.8).

CARDIOVASCULAR EVENTS IN AGED PCOS A more instructive study, because it included a large number of women and therefore had substantial statistical power, is the Nurses Health Study (NHS), which followed 82,439 women for 14 years. The women with very irregular menses had a significantly increased relative risk of 1.5 (CI: 1.3-1.9) for coronary heart disease and 1.9 (CI: 1.3-2.7) for fatal myocardial infarction compared with eumenorrheic women. Since oligomenorrhea is an excellent surrogate marker for PCOS, these findings lend strong epidemiological support to the idea of increased cardiovascular risk in PCOS.

CARDIOVASCULAR EVENTS IN AGED PCOS The findings of the NHS were corroborated by a sub study of the Women s Ischemia Evaluation Study (WISE) (Shaw et al JCEM 2008; 93:1276-84). 104 postmenopausal women with PCOS (defined as oligomenorrhea during the premenopausal years and elevated serum testosterone) were identified and followed prospectively for close to 10 years. Multivessel cardiovascular disease was observed in 32% of PCOS women compared to 25% of non-pcos women (odd ratio 1.7) and it correlated with several factors, including persisting postmenopausal hyperandrogenism However, this study has been withdrawn because of a NIH evaluation found several mistakes in data collection

LEICESTER STUDY A recent study has claimed important increase of cardiovascular events in aged PCOS women (Mani H et al. Clin Endocrinol 2013; 78:926-934) At the end of 20 years follow-up, the prevalence of MI in the age groups was: 45 54 years: 1.9 % 55 64 years: 6 % >65 years: 27.3 % Odd ratios for the prevalence of MI compared to the local female population was 12 9 (CI: 3 4 48 6) in the group >65 years old

LEICESTER STUDY However: Only 11 patients had more than 65 years Only 83 patients had more than 55 years

CV EVENTS IN AGED PCOS WOMEN In an other small (Schmidt et al. JCEM 2011; 96:3794-3803) study, 21 PCOS patients were followed until their 60s and number of CV events was similar to that found in normal women of similar age

CV EVENTS IN AGED PCOS WOMEN Large and well planed follow up studies are needed to demonstrate increases of CV events in aged PCOS patients However, available data suggest that the number of CV events in aged PCOS patients is slightly increased but lower than that expected on the basis of risk calculation during young age

CV EVENTS IN PCOS: SUMMARY A 3-4 times increase of cardiovascular events in young PCOS women is probable but still not demonstrated Anyway the number of events during young reproductive age is very low and also its increase of 3-4 times may not be sufficient to increase the total number of CV events in PCOS In aged PCOS the CV events are normal or slightly elevated

DISCREPANCY BETWEEN CV RISKS AND EVENTS IN AGED PCOS The mechanisms of the discrepancy between CV risk and late events in PCOS are unclear Progressive normalization of CV risk during late reproductive age may have a main role Flexibility of CV system is much higher during reproductive age than in aged population

CHANGES OF THE EXPRESSION OF PCOS DURING LATE REPRODUCTIVE AGE During late reproductive age, probably because of spontaneous reduction of ovarian and adrenal androgens, in a subgroup of patients the severity of PCOS reduces and in some patients the syndrome may disappear These spontaneous changes are very important for the future life of the patients with PCOS and our counseling should take in account the different possible evolutions of the disorder

CHANGES OF THE EXPRESSION OF PCOS DURING LATE REPRODUCTIVE AGE Moving from 20-25 to 40-45 years age, in PCOS the following changes occur: Androgen secretion reduces by 20-30% Ovulation appears in about 50% of PCOS patients A number of these women will have spontaneous pregnancies and children These changes influence not only the reproductive life but also the metabolic and CV risk of PCOS patients

IMPROVEMENT OF PCOS DURING LATE REPRODUCTIVE AGE REDUCES CARDIOVASCULAR RISK EMERGENCE OF OVULATORY CYCLES WITH AGING IN WOMEN WITH POLYCYSTIC OVARY SYNDROME (PCOS) ALTERS THE TRAJECTORY OF CARDIOVASCULAR AND METABOLIC RISK FACTORS Carmina E, Campagna AM, Lobo RA Hum Reprod 2013, 28:2245-52 Conclusions: Prevalence of metabolic syndrome and dyslipidemia tend to normalize with aging. It is mainly depending on improvement of lipid parameters in women who attain ovulatory cycles.

PREVALENCE OF METABOLIC SYNDROME IN PCOS WOMEN OF DIFFERENT REPRODUCTIVE AGE 20 15 10 % 5 0 % Third decade of age Fifth decade of age PCOS Female population Carmina et al. Hum Reprod 2013; 28:2245-52

LDL VALUES IN 2 GROUPS OF PCOS PATIENTS WHO WERE FOLLOWED FOR 20 YEARS LDL-cholesterol at a mean age of 42 years 160 ** 120 mg/dl 80 Patients becoming ovulatory with age Patients remaining anovulatory with age ** p<0.01 Carmina et al. Hum Reprod 2013; 28:2245-52

APPEARANCE OF OVULATORY CYCLES DURING LATE REPRODUCTIVE AGE ATTENUATES CV RISK IN PCOS The occurrence of ovulatory function during late reproductive age in women with PCOS is associated with an attenuation of cardiovascular risk. A negative correlation was observed between the appearance of ovulatory cycles and the increase in LDL-cholesterol. In patients who remained anovulatory, total, LDL-cholesterol and non-hdlcholesterol values significantly increased and prevalence of metabolic syndrome and CV risk remained significantly higher than in general population.

IMPROVEMENT OF CARDIOVASCULAR RISK DURING REPRODUCTIVE AGE IN YOUNG PCOS WOMEN Other studies (Tehrani et al. Plos One 2015, Sep 11, Epub) have suggested that the cardiovascular risk tends to normalize with age in PCOS Young PCOS women followed for a mean period of 6 years presented tendency to normalize their risk linked to altered lipid profile and insulin resistance

AGING ATTENUATES CV RISK IN PCOS All these factors determine a generalized reduction of cardiovascular risk in PCOS women when they approach menopause. However, the population of PCOS women remain heterogeneous with some women presenting normalization of cardiovascular risk and others remaining with a substantial risk

DIVERGENT EVOLUTION OF TWO SUBGROUPS OF PCOS DURING LATE REPRODUCTIVE AGE There is a divergent evolution of two groups of women with PCOS during their late reproductive age One subgroup improves its reproductive function and reduces the cardiovascular risk Another subgroup continues to have altered reproductive function and high metabolic and cardiovascular risk

INCREASE OF CV RISK FACTORS IN PCOS DURING LATE REPRODUCTVE AGE Total Cholesterol NON-HDL C LDL-C Metabolic Syndrome Patients who remain anovulatory ++ ++ ++ + Patients who become ovulatory + NO NO NO

LONG TERM MANAGEMENT OF PCOS WOMEN The emerging data on changes in metabolic and cardiovascular risk with age in PCOS have complicated our approach to long term management of young PCOS women. What should we do? Treat all young women with PCOS who present a risk? Wait until the age of 40s to concentrate the treatment in women who do not normalize or substantially improve their risk?

LONG TERM MANAGEMENT OF PCOS WOMEN No clear answer exists to these questions and many more and more prolonged follow up studies are needed. However, a rational approach may be that to limit the treatment only to young patients presenting more severe metabolic involvement. In fact, data on prevalence of type Ii diabetes with age seem to indicate a high risk of conversion from altered glucose tolerance to overt diabetes in reproductive age patients. Therefore, altered glucose tolerance should always be actively treated also during young age.

LONG TERM MANAGEMENT OF PCOS WOMEN Patients who do not present altered glucose tolerance but present increased cardiovascular risk may probably wait until the age of 40s. At that time, a careful analysis of CV risk should be performed and all patients with increased CV risk should be actively treated.